On Thursday, Sangamo Biosciences, Inc. (NASDAQ:SGMO)’s shares declined -7.77% to $11.51.
Sangamo Biosciences, Inc. (SGMO) declared that it will consolidate development paths for the zinc finger nuclease (ZFN)-mediated genome editing programs targeting beta-thalassemia and sickle cell disease (SCD). This decision was based on preclinical data that support the development of the “BCL11A Enhancer” target for these clinical programs, indicating that it has the potential to provide the most efficient path to clinical proof of concept and subsequent development. While the beta-thalassemia program was initiated with a BCL11a knockout strategy, the SCD program already employs the BCL11A Enhancer approach. The decision to consolidate the strategy for these two programs was made by the joint steering committee (JSC) governing the programs, counting Sangamo’s collaborator Biogen.
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for unmet medical needs in the United States.
LiveDeal Inc (NASDAQ:LIVE)’s shares dropped -7.01% to $3.05.
LiveDeal Inc (LIVE) declares financial results from its fiscal second quarter, which ended March 31, 2015.
The company’s revenues for Q2 2015 were nearly $4.3 million, an enhance of 529 percent over the same period the year preceding.
Other highlights comprise:
Gross profit of $1.93 million, an enhance of almost 348 percent contrast to the same time period the previous year
The company’s cash position continues to be strong, with nearly $7.2 million in cash and cash equivalents, contrast to $6.5 million from the previous quarter
The company has put noteworthyresources into advertising and marketing
LiveDeal, Inc., together with its auxiliaries, provides specialized online marketing solutions for small and medium-sized local businesses in the United States.
At the end of Thursday’s trade, Willbros Group Inc (NYSE:WG)‘s shares dipped -5.98% to $2.35.
Willbros Group Inc (WG) declared results for the first quarter 2015. The Company stated a net loss in the first quarter of $9.8 million, or $0.20 per share, on revenue of $346.9 million, contrast to a net loss of $25.0 million, or $0.51 per share, on revenue of $476.5 million for the same period in 2014. First quarter 2015 operating income was $35.2 million contrast to an operating loss of $5.6 million in 2014. The first quarter results comprised of a $58.5 million, or $1.18 per share, gain on the sale of auxiliaries, and debt covenant suspension and extinguishment charges of $35.9 million, or $0.72 per share, associated with the early payment of term loan debt and the suspension of debt covenants through March 31, 2016, in addition to other charges of $4.0 million counting asset impairment, lease abandonment and employee severance expenses.
Willbros Group, Inc., together with its auxiliaries, operates as an energy infrastructure contractor serving the oil, gas, refining, petrochemical, and power industries in the United States and internationally. It provides engineering, procurement, and construction (EPC); and turnarounds, maintenance, facilities development, and operations services. The company operates through four segments: Oil & Gas, Professional Services, Utility T&D, and Canada.
ImmunoGen, Inc. (NASDAQ:IMGN), ended its Thursday’s trading session with -6.25% loss, and closed at $8.55.
ImmunoGen, Inc. (IMGN) offered information on ImmunoGen-related presentations to take place at the 2015 American Society of Clinical Oncology (ASCO) annual meeting being held May 29-June 2 in Chicago, IL.
ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
